Titan sees Braeburn as best partner to secure future of Probuphine
This article was originally published in Scrip
Executive Summary
Titan Pharmaceuticals insists that multiple potential partners were interested in commercializing Probuphine (buprenorphine) in the US and Canada, but the company's executives said they signed a license deal with the startup firm Braeburn Pharmaceuticals to reduce the risk that the opioid addiction therapy delivered by a novel subdermal implant would be de-prioritized by a Big Pharma player.
You may also be interested in...
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.